Complementary Transcatheter Therapy for Mitral Regurgitation

Sorajja, Paul; Bae, Richard; Gössl, Mario; Askew, Judah; Jappe, Kate; Schneider, Lynelle; Sun, Benjamin

doi:10.1016/j.jacc.2018.12.035

Cited by 12 publications

(8 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Repair techniques that include combinations of these approaches have also been explored. [13][14][15] TMVR platforms are in earlier stages of clinical development. 16 To date, the largest transcatheter clinical experience has been with leaflet repairs, specifically, percutaneous, edgeto-edge leaflet repair, in which the anterior and posterior leaflets of the MV are approximated to restore coaptation and create a double orifice valve.…”

Section: Introduction Backgroundmentioning

confidence: 99%

2019 AATS/ACC/SCAI/STS expert consensus systems of care document: Operator and institutional recommendations and requirements for transcatheter mitral valve intervention

Bonow

O’Gara

Adams

et al. 2020

The Journal of Thoracic and Cardiovascular Surgery

View full text Add to dashboard Cite

Section: Introduction Backgroundmentioning

confidence: 99%

2019 AATS/ACC/SCAI/STS expert consensus systems of care document: Operator and institutional recommendations and requirements for transcatheter mitral valve intervention

Bonow

O’Gara

Adams

et al. 2020

The Journal of Thoracic and Cardiovascular Surgery

View full text Add to dashboard Cite

“…Implantation of the Tendyne transapical TMVI prosthesis has been shown to be safe and highly effective for patients at prohibitive surgical risk, and early experiences have facilitated an expansion of adjunctive techniques and applications 7,8,[18][19][20][21] . Procedural mortality for the high-risk cohort receiving Tendyne TMVI remains zero with echocardiographic results of MR <1+.…”

Section: Discussionmentioning

confidence: 99%

Mitral regurgitation severity predicts one-year therapeutic benefit of Tendyne transcatheter mitral valve implantation

Badhwar

Sorajja²,

Duncan³

et al. 2019

EuroIntervention

Self Cite

View full text Add to dashboard Cite

Aims: Longitudinal outcomes of transcatheter therapies for secondary mitral regurgitation (MR) have been variable. This study examined predictors of one-year outcome following transcatheter mitral valve implantation (TMVI) with the Tendyne device. Methods and results:The first 100 consecutive patients with moderate-severe or severe MR enrolled in the Tendyne CE Mark trial were examined. Multivariable analyses assessed the impact of preoperative clinical and echocardiographic characteristics on one-year freedom from death or heart failure hospitalisation (HFH). All 100 patients underwent Tendyne TMVI without operative mortality. Univariate analysis was performed on implanted subjects, followed by multivariate analysis in those with complete predictive variable data. Patient characteristics: 76.5% male, 60.8% NYHA Class III/IV, age 75.6±7.5 years and Society of Thoracic Surgeons predicted risk of mortality of 8.5±6.1%. Increased left ventricular end-diastolic dimension was associated with one-year Tendyne benefit following univariate analysis (OR 0.35, p=0.010). Following multivariable adjustment, only severe MR, defined as a composite of effective regurgitant orifice area ≥0.3 cm 2 or regurgitant volume ≥45 ml, was associated with freedom from death or HFH at one year (OR 0.16, p=0.032).Conclusions: Preoperative severe MR was predictive of improved one-year outcome following Tendyne TMVI. These results may inform therapy selection for the management of secondary MR and left ventricular dilatation.

show abstract

“…In these instances, TMVR can be considered by using catheter-based electrosurgical techniques to cut the anterior mitral tissue bridge and placement of the device. This would potentially eliminate the MR. 45,46 There is a wealth of data on the excellent safety profile of TEER technology with MitraClip and, more recently, with PASCAL. The candidacy for TEER can be quickly established with TEE, and most patients can be discharged on the following day.…”

Section: Teer Versus Tmvr In Smr: How To Choose?mentioning

confidence: 99%

10 Commandments of TEER in Patients With Secondary Mitral Regurgitation

Gedela

2023

Innovations�(Phila)

View full text Add to dashboard Cite

Complementary Transcatheter Therapy for Mitral Regurgitation

Cited by 12 publications

References 3 publications

2019 AATS/ACC/SCAI/STS expert consensus systems of care document: Operator and institutional recommendations and requirements for transcatheter mitral valve intervention

2019 AATS/ACC/SCAI/STS expert consensus systems of care document: Operator and institutional recommendations and requirements for transcatheter mitral valve intervention

Mitral regurgitation severity predicts one-year therapeutic benefit of Tendyne transcatheter mitral valve implantation

10 Commandments of TEER in Patients With Secondary Mitral Regurgitation

Contact Info

Product

Resources

About